Decreased Expression of TGR5 in Vogt-Koyanagi-Harada (VKH) Disease

REFERENCES

• Damico FM, Cunha-Neto E, Goldberg AC, et al. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis[J]. Invest Ophthalmol Vis Sci. 2005;46(7):2465–2471. doi:10.1167/iovs.04-1273.
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt–Koyanagi–Harada syndrome in Chinese patients[J]. Ophthalmology. 2007;114(3):606–614.e3. doi:10.1016/j.ophtha.2006.07.040.
   PubMed Web of Science ®Google Scholar
• Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment[J]. Prog Retinal Eye Res. 2016;52:84–111. doi:10.1016/j.preteyeres.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Ohta K, Yoshimura N. Bcl-2 expression by CD4 T lymphocytes in Vogt-Koyanagi-Harada disease[J]. Ocul Immunol Inflammation. 2002;10(2):93–103. doi:10.1076/ocii.10.2.93.13984.
   PubMed Web of Science ®Google Scholar
• Chi W, Yang P, Li B, et al. IL-23 promotes CD4 +, T cells to produce IL-17 in Vogt-Koyanagi-Harada disease[J]. J Allergy Clin Immunol. 2007;119(5):1218–1224. doi:10.1016/j.jaci.2007.01.010.
   PubMed Web of Science ®Google Scholar
• Ng JY, Luk FO, Lai TY, Pang C-P. Influence of molecular genetics in Vogt-Koyanagi-Harada disease[J]. J Ophthalmic Inflamm Infect. 2014;4(1):20. doi:10.1186/s12348-014-0020-1.
   PubMedGoogle Scholar
• Fujiwara N, Kobayashi K. Macrophages in inflammation[M]. Adipose Tissue Biol. 2005;167–193. doi:10.2174/1568010054022024.
   Google Scholar
• Melton DW, McManus LM, Gelfond JA, Shireman PK. Temporal phenotypic features distinguish polarized macrophages in vitro. Autoimmunity. 2015;48(3):161–176. doi:10.3109/08916934.2015.1027816.
   PubMed Web of Science ®Google Scholar
• Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. doi:10.1016/j.immuni.2014.06.008.
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation[J]. Nat Rev Immunol. 2008;8(12):958–969. doi:10.1038/nri2448.
   PubMed Web of Science ®Google Scholar
• Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. 2004;76(3):509–513. doi:10.1189/jlb.0504272.
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages[J]. Nat Rev Immunol. 2003;3(1):23–35. doi:10.1038/nri978.
   PubMed Web of Science ®Google Scholar
• Lopes FB, Bálint Š, Valvo S, et al. Membrane nanoclusters of FcγRI segregate from inhibitory SIRPα upon activation of human macrophages[J]. J Cell Biol. 2017;216(4):1123–1141. doi:10.1083/jcb.201608094.
   PubMed Web of Science ®Google Scholar
• Tq DAV, Tarling EJ, Edwards PA. Pleiotropic roles of Bile acids in metabolism[J]. Cell Metab. 2013;17(5):657–669. doi:10.1016/j.cmet.2013.03.013.
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JYL. Bile acid signaling in metabolic disease and drug therapy[J]. Pharmacol Rev. 2014;66(4):948–983. doi:10.1124/pr.113.008201.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484–489. doi:10.1038/nature04330.
   PubMed Web of Science ®Google Scholar
• Yoneno K, Hisamatsu T, Shimamura K, et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn’s disease. Immunology. 2013;139(1):19–29. doi:10.1111/imm.12045.
   PubMed Web of Science ®Google Scholar
• Biagioli M, Carino A, Cipriani S, et al. The bile acid receptor Gpbar1 regulates the M1/M2 phenotype of intestinal macrophages and activation of Gpbar1 rescues mice from Murine Colitis[J]. J Immunol. 2017;199(2):718–733. doi:10.4049/jimmunol.1700183.
   PubMed Web of Science ®Google Scholar
• Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14(6):747–757. doi:10.1016/j.cmet.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature[J]. Am J Ophthalmol. 2001;131(5):647–652.
   PubMed Web of Science ®Google Scholar
• Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin[J]. Cell Immunol. 2013;281(1):51–61. doi:10.1016/j.cellimm.2013.01.010.
   PubMed Web of Science ®Google Scholar
• Lee MK, Moore XL, Fu Y, et al. High-density lipoprotein inhibits human M1 macrophage polarization through redistribution of caveolin-1. Br J Pharmacol. 2016;173(4):741–751. doi:10.1111/bph.13319.
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids[J]. J Biol Chem. 2003;278(11):9435–9440. doi:10.1074/jbc.M209706200.
   PubMed Web of Science ®Google Scholar
• Lewis ND, Patnaude LA, Pelletier J, et al. A Gpbar1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo. PLoS One. 2014;9(6):e100883. doi:10.1371/journal.pone.0100883.
   PubMed Web of Science ®Google Scholar
• Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap–bile acids in metabolic control[J]. Nat Rev Endocrinol. 2014;10(8):488–498. doi:10.1038/nrendo.2014.60.
   PubMed Web of Science ®Google Scholar
• Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development[J]. Nat Rev Gastroenterol Hepatol. 2014;11(1):55–67. doi:10.1038/nrgastro.2013.151.
   PubMed Web of Science ®Google Scholar
• Sato H, Genet C, Strehle A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea[J]. Biochem Biophys Res Commun. 2007;362(4):793–798. doi:10.1016/j.bbrc.2007.06.130.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Gioiello A, Macchiarulo A, et al. Discovery of 6α-Ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity[J]. J Med Chem. 2009;52(24):7958–7961. doi:10.1021/jm901390p.
   PubMed Web of Science ®Google Scholar
• Guo C, Chen WD, Wang YD. TGR5, not only a metabolic regulator[J]. Front Physiol. 2016;7. doi:10.3389/fphys.2016.00646.
   Web of Science ®Google Scholar
• Duboc H, Taché Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application[J]. Digestive Liver Dis. 2014;46(4):302–312. doi:10.1016/j.dld.2013.10.021.
   Web of Science ®Google Scholar
• Baghdasaryan A, Claudel T, Gumhold J, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology. 2011;54(4):1303–1312. doi:10.1002/hep.24537.
   PubMed Web of Science ®Google Scholar
• Guo C, Qi H, Yu Y, et al. The G-protein-coupled bile acid receptor Gpbar1 (TGR5) inhibits gastric inflammation through antagonizing NF-κB signaling pathway. Front Pharmacol. 2015;6:287. doi:10.3389/fphar.2015.00287.
   PubMed Web of Science ®Google Scholar
• Haselow K, Bode JG, Wammers M, et al. Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J Leukoc Biol. 2013;94(6):1253–1264. doi:10.1189/jlb.0812396.
   PubMed Web of Science ®Google Scholar
• Anower AKMM, Ju AS, Choi B, Kwon HJ, Sohn S. The role of classical and alternative macrophages in the immunopathogenesis of herpes simplex virus-induced inflammation in a mouse model[J]. J Dermatol Sci. 2014;73(3):198–208. doi:10.1016/j.jdermsci.2013.11.001.
   PubMed Web of Science ®Google Scholar
• Zhu W, Yu J, Nie Y, et al. Disequilibrium of M1 and M2 macrophages correlates with the development of experimental inflammatory bowel diseases[J]. Immunol Invest. 2014;43(7):638–652. doi:10.3109/08820139.2014.909456.
   PubMed Web of Science ®Google Scholar
• Huang X, Ye Z, Cao Q, et al. Gut microbiota composition and fecal metabolic phenotype in patients with acute anterior uveitis[J]. Invest Ophthalmol Vis Sci. 2018;59(3):1523–1531. doi:10.1167/iovs.17-22677.
   PubMed Web of Science ®Google Scholar
• Ye Z, Zhang N, Wu C, et al. A metagenomic study of the gut microbiome in Behcet’s disease[J]. Microbiome. 2018;6(1):135. doi:10.1186/s40168-018-0432-5.
   PubMed Web of Science ®Google Scholar